Healthcare

HCA Healthcare Reports Third Quarter 2025 Results

Raises 2025 GuidanceNASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the third quarter ended…

2 months ago

Tutor.com Honored with 2025 CODiE Award for Best Customer Experience Solution for Education

NEW YORK, Oct. 24, 2025 /PRNewswire/ -- Tutor.com, a leading innovator in online tutoring and education solutions, today announced that…

2 months ago

The Craneware Group Announces Full Trisus® Portfolio Co-Sell-Ready and Available in the Microsoft Azure Marketplace

Microsoft Azure customers worldwide can now access The Craneware Group's full portfolio of co-sell-ready Trisus® SaaS solutions, leveraging the scalability,…

2 months ago

Terumo Interventional Systems Announces Its New OPUSWAVE® Dual Sensor Imaging System and DualView® Imaging Catheter Receive FDA 510(k) Clearance

OPUSWAVE Imaging System combines OFDI and IVUS into a single catheter, providing significant potential to reduce procedural time and costs…

2 months ago

Weekly Recap: 12 Tech Press Releases You Need to See

A roundup of the most newsworthy tech announcements from PR Newswire this week, including the release of VERA-MH by Spring Health…

2 months ago

Medical Care Technologies Inc. (OTC PINK:MDCE) Approved as Official Apple Developer

Company advances digital technology initiatives with approval to publish applications on Apple's App Store MESA, ARIZONA / ACCESS Newswire /…

2 months ago

Interactive Strength Inc. (NASDAQ: TRNR) to Release Third-Quarter Results on Friday, November 14, 2025

AUSTIN, TEXAS / ACCESS Newswire / October 24, 2025 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or the "Company"), maker of…

2 months ago

MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication

Advancing toward Phase 2a clinical evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast…

2 months ago

NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia (FD) with associated Nausea Symptoms in the Adult Patient Population

Achieves significant expansion of NeurAxis’ total addressable marketClearance now includes patients aged “8 years and older”Expanded age indication will utilize…

2 months ago